taurine has been researched along with Huntington Disease in 8 studies
Huntington Disease: A familial disorder inherited as an autosomal dominant trait and characterized by the onset of progressive CHOREA and DEMENTIA in the fourth or fifth decade of life. Common initial manifestations include paranoia; poor impulse control; DEPRESSION; HALLUCINATIONS; and DELUSIONS. Eventually intellectual impairment; loss of fine motor control; ATHETOSIS; and diffuse chorea involving axial and limb musculature develops, leading to a vegetative state within 10-15 years of disease onset. The juvenile variant has a more fulminant course including SEIZURES; ATAXIA; dementia; and chorea. (From Adams et al., Principles of Neurology, 6th ed, pp1060-4)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cystamine is beneficial to Huntington disease (HD) transgenic mice." | 7.73 | Treatment of YAC128 mice and their wild-type littermates with cystamine does not lead to its accumulation in plasma or brain: implications for the treatment of Huntington disease. ( Cooper, AJ; Hayden, MR; Jeitner, TM; Krasnikov, BF; Leavitt, BR; Pinto, JT; Thaler, HT; Van Raamsdonk, JM, 2005) |
| "Cystamine is beneficial to Huntington disease (HD) transgenic mice." | 3.73 | Treatment of YAC128 mice and their wild-type littermates with cystamine does not lead to its accumulation in plasma or brain: implications for the treatment of Huntington disease. ( Cooper, AJ; Hayden, MR; Jeitner, TM; Krasnikov, BF; Leavitt, BR; Pinto, JT; Thaler, HT; Van Raamsdonk, JM, 2005) |
| "Taurine pretreatment also caused about 2-fold increase in GABA concentration compared to 3-NP-treated animals." | 1.33 | Neuroprotective effect of taurine in 3-nitropropionic acid-induced experimental animal model of Huntington's disease phenotype. ( Abdel-Naim, AB; Arafa, HM; Khalifa, AE; Tadros, MG, 2005) |
| "Taurine is a sulfonic amino acid with inhibitory effects in the central nervous system." | 1.28 | Taurine treatment of dyskinesias: an attempt. ( Blom, H; Engelsen, BA; Nyland, H, 1989) |
| "Quinolinic acid (QA) is an endogenous excitotoxin present in mammalian brain that reproduces many of the histologic and neurochemical features of Huntington's disease (HD)." | 1.27 | Systemic approaches to modifying quinolinic acid striatal lesions in rats. ( Beal, MF; Ferrante, RJ; Kowall, NW; Martin, JB; Swartz, KJ, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (62.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tsang, TM | 1 |
| Haselden, JN | 1 |
| Holmes, E | 1 |
| Pinto, JT | 1 |
| Van Raamsdonk, JM | 1 |
| Leavitt, BR | 1 |
| Hayden, MR | 1 |
| Jeitner, TM | 1 |
| Thaler, HT | 1 |
| Krasnikov, BF | 1 |
| Cooper, AJ | 1 |
| Tadros, MG | 1 |
| Khalifa, AE | 1 |
| Abdel-Naim, AB | 1 |
| Arafa, HM | 1 |
| Kish, SJ | 1 |
| Shannak, KS | 1 |
| Perry, TL | 2 |
| Hornykiewicz, O | 1 |
| Beal, MF | 1 |
| Kowall, NW | 1 |
| Swartz, KJ | 1 |
| Ferrante, RJ | 1 |
| Martin, JB | 1 |
| Nyland, H | 1 |
| Engelsen, BA | 1 |
| Blom, H | 1 |
| Bonilla, E | 1 |
| Prasad, AL | 1 |
| Arrieta, A | 1 |
| Hansen, S | 1 |
| Kloster, M | 1 |
8 other studies available for taurine and Huntington Disease
| Article | Year |
|---|---|
Metabonomic characterization of the 3-nitropropionic acid rat model of Huntington's disease.
Topics: Animals; Behavior, Animal; Brain; Brain Stem; Cerebellum; Cerebral Cortex; Choline; Corpus Striatum; | 2009 |
Treatment of YAC128 mice and their wild-type littermates with cystamine does not lead to its accumulation in plasma or brain: implications for the treatment of Huntington disease.
Topics: Animals; Brain; Chromatography, High Pressure Liquid; Colorimetry; Cystamine; Cysteamine; Female; Gl | 2005 |
Neuroprotective effect of taurine in 3-nitropropionic acid-induced experimental animal model of Huntington's disease phenotype.
Topics: Animals; Corpus Striatum; Disease Models, Animal; gamma-Aminobutyric Acid; Huntington Disease; Male; | 2005 |
Neuronal [3H]benzodiazepine binding and levels of GABA, glutamate, and taurine are normal in Huntington's disease cerebellum.
Topics: Amino Acids; Cerebellum; Flunitrazepam; gamma-Aminobutyric Acid; Glutamates; Glutamic Acid; Haloperi | 1983 |
Systemic approaches to modifying quinolinic acid striatal lesions in rats.
Topics: 2-Amino-5-phosphonovalerate; Allopurinol; Amino Acids; Animals; Antioxidants; Baclofen; Corpus Stria | 1988 |
Taurine treatment of dyskinesias: an attempt.
Topics: Administration, Oral; Adult; Aged; Calcinosis; Cerebral Cortex; Female; Humans; Huntington Disease; | 1989 |
Huntington's disease: studies on brain free amino acids.
Topics: Adult; Aged; Aged, 80 and over; Amino Acids; Aspartic Acid; Brain; Female; gamma-Aminobutyric Acid; | 1988 |
Huntington's chorea. Deficiency of gamma-aminobutyric acid in brain.
Topics: Amino Acid Metabolism, Inborn Errors; Amino Acids; Aminobutyrates; Autopsy; Basal Ganglia; Brain; Br | 1973 |